Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead

Muscle and Nerve

Volumn 45, Issue 3, 2012, Pages 311-318

  Blackhall, Leslie J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Amyotrophic lateral sclerosis; End of life; Pain management; Palliative care; Symptom management

Indexed keywords

AMITRIPTYLINE; ATROPINE; BACLOFEN; DANTROLENE; DEXTROMETHORPHAN; DIAZEPAM; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; METHYLPHENIDATE; MIRTAZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; QUINIDINE; QUININE; SCOPOLAMINE; TIZANIDINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ARTHRALGIA; DEPRESSION; DRUG EFFICACY; DYSPNEA; FAMILY DECISION MAKING; HUMAN; HYPERSALIVATION; LOW ENERGY RADIATION; MEDICAL DECISION MAKING; MOOD DISORDER; MUSCLE CRAMP; MYALGIA; PALLIATIVE THERAPY; PATIENT CARE; PATIENT DECISION MAKING; PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SPASTICITY; TERMINAL CARE;

AMYOTROPHIC LATERAL SCLEROSIS; DECISION MAKING; DYSPNEA; HUMANS; MOOD DISORDERS; PAIN MANAGEMENT; PALLIATIVE CARE; RESPIRATORY INSUFFICIENCY; SIALORRHEA;

EID: 84857088346     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22305     Document Type: Review

References (108)

1. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
2. van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff M, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65:1264-1267.
3. Traynor BJ, Alexander M, Corr B, Frost E, Hardimanet O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population-based study. J Neurol Neurosurg Psychiatry 2003;74:1258-1261.
4. Saunders C, Walsh TE, Smith M. Hospice care in motor neuron disease. In: Saunders C, Summers DH, Teller N, editors. Hospice: the living idea. London: Edward Arnold; 1981.
5. Miller RG, Moore DH, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
6. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999;521:434-1440.
7. O'Brien T, Kelly M, Saunders C. Motor neurone disease: a hospice perspective BMJ 1992;304:471-473.
8. Brettschneider J, Kurent J, Ludolph A, Mitchell JD. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease (review). Cochrane Database Syst Rev 2008 July 16;(3):CD005226.
9. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1985;48:838-840.
10. Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology 2002;59:428-431.
11. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al., And the ALS Practice Parameters Task Force. Practice parameter: The care of the patient with ALS (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1999;52;1311-1323.
12. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73; 1227-1233.
13. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 2001;19:829-847.
14. Forshew DA, Bromberg MB. A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotroph Lat Scler Other Motor Neuron Disord 2003;4:258-263.
15. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;9(suppl 1):30-34.
16. Drug products for the treatment and/or prevention of nocturnal leg muscle cramps for over-the-counter human use, 59 Federal Register 43234 (August 22, 1994).
17. Nance PW, Sheremata, WA, Lynch SG, Vollmer T, Hudson S, Francis GS, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997;54:731-736.
18. Norris F, U K, Sachais B, Carey M. Trial of bacolfen in amyotrophic lateral sclerosis. Arch Neurol 1979;36:715-716.
19. McClelland S, Bethoux FA, Boulis NM, Sutliff MH, Stough DK, Schwetz KM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve 2008;37:396-398.
20. Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001;191:133-137.
21. Kübler A, Winter S, Albert C, Martin Hautzinger M, Birbaumer N. Severity of depressive symptoms and quality of life in patients with amyotrophic lateral sclerosis. Neurorehabil Neural Repair 2005;19: 182-193.
22. Wicks P, Abrahams S, Masia D, Hejda-Forde S, Leigh PN, Goldstein LH. Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol 2007;14:993-1001.
23. Rabkin JG, Albert SM, Del Bene ML, O'Sullivan I, Tider T, Rowland LP, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 2005;65:62-67.
24. Bocker FM, Siebold I, Neundorfer B. Disability in everyday tasks and subjective status of patients with advanced amyotrophic lateral sclerosis. Fortschr Neurol Psychiatry 1990;58:224-236.
25. Hammer EM, Häcker S, Hautzinger M, Meyer TD, Kübler A. Validity of the ALS Depression Inventory (ADI-12)-a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord 2008;109:213-219.
26. Albert SM, Rabkin JG, Del Bene ML, O'Sullivan I, Tider T, Rowland LP, et al. Wish to die in end-stage ALS. Neurology 2005;65: 68-74.
27. Lou J-S, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology 2003;60: 122-123.
28. Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol 2007;61:92-96.
29. Ganzini L, Silveira MJ, Johnston WS. Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington. J Pain Symp Manag 2002;3: 312-317.
30. Olney RK, Lomen-Hoerth C. Exit strategies in ALS: an influence of depression or despair? Neurology 2005;65:9-10.
31. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902.
32. Saletu-Zyhlarz GM, Anderer P, Arnold O, Saletu B. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology 2003;48:194-208.
33. Hinshaw DB, Carnahan JM, Johnson DL. Depression, anxiety, and asthenia in advanced illness. J Am Coll Surg 2002;195:271-277.
34. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinal (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-183.
35. Terzoudi M, Gavrielidou O, Heilakos G. Fatigue in multiple sclerosis. Evaluation and a new pharmacological approach. Neurology 2000;54(suppl 3):A61.
36. Blackhall LJ, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med 2009;12:433-439.
37. Fava M, Thase ME, Debattista C. A multi-center, placebo-controlled study of modafinal augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85-93.
38. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 2004; 15:712-720.
39. Carter GT, Weiss MD, Lou J-S, Jensen MP, Abresch RT, Martin TK, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005;22:55.
40. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo controlled study. Muscle Nerve 2009;39:297-303.
41. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985;312: 1480-1482.
42. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K. Fluoxetine improves emotional incontinence. Brain Inj 1992;6:267-270.
43. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342:837-839.
44. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993;150:286-293.
45. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999;14:681-685.
46. Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al., For the AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.
47. Bradley WG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, et al. Current management of ALS: comparison of the ALS CARE database and the AAN practice parameter. Neurology 2001; 57:500-504.
48. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2008;39: 137-143.
49. Kohler PF, Winter ME. A quantitative test for xerostomia. Arthritis Rheum 1985;28:1128-1132.
50. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-247.
51. Cederbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS Functional Rating Scale that incorporates assessments of respiratory function. J Neurol Sci 1999; 169:13-21.
52. Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 2006; 32:235-237.
53. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997;157:1531-1536.
54. Simmons Z. Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. The Neurologist 2005;11:257-270.
55. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-1281.
56. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-123.
57. Lagalla G, Millevolte M, Capecci C, Provinciali M, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009;256:563-567.
58. Bhatia KKP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling of saliva. J Neurol Neurosurg Psychiatry 1999;67:697.
59. Winterholler MGM, Erbguth FJ. Botulinum toxin for the treatment of sialorrhoea in ALS; serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001;70:406-425.
60. Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001;30:242-245.
61. Andersen PM, Gronberg H, Franze L, Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbarparesis. J Neurol Sci 2001;191:111-114.
62. Mandler RN, Anderson FA Jr, Miller RG, Clawson L, Cudkowicz M, Del Bene M, and the ALS C.A.R.E. Study Group. The ALS Patient Care Database: insights into end of-life care in ALS. ALS Other Motor Neuron Disord 2001;2:203-208.
63. Barthlena GM, Langeba DJ. Unexpectedly severe sleep and respiratory pathology in patients with amyotrophic lateral sclerosis. Eur J Neurol 2000;7:299-302.
64. Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ. Noninvasive ventilation in ALS indications and effect on quality. Neurology 2003;61:171-177.
65. Maessen M, Veldink JH, van den Berg LH, Schouten HJ, van der Wal G, Onwuteaka-Philipsen BD. Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients. J Neurol 2010; 257:1192-1198.
66. Piper AJ, Sullivan CE. Effects of long-term nocturnal nasal ventilation on spontaneous breathing during sleep in neuromuscular and chest wall disorders. Eur Respir J 1996;9:1515-1522.
67. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ ALS patients: survival rates in controlled trials. J Neurol Sci 1995; 129(suppl):19-26.
68. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5:140-147.
69. Lyall A, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, et al. A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 2001;57:153-156.
70. Bradley WG, Anderson F, Gowda N, Miller RG,and the ALS CARE Study Group. Changes in the management of ALS since the publication of the AAN ALS practice 1999. ALS Other Motor Neuron Dis 2004;5:240-244.
71. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997;127:450-453.
72. Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005;65:1774-1777.
73. Jackson C, Lovitt S, Gowda N, et al., And the ALS Care Study Group. Factors correlated with NPPV use in ALS. Amyotroph Lateral Scler 2006;7:80-85.
74. Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Sympt Manag 1990;5:341-344.
75. Clemens K, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care. J Pain Sympt Manag 2007;33:473-481.
76. Chan JD, Treece PD, Engleberg RA, Crowley L, Rubenfeld GD, Steinberg KP, et al. Narcotic and benzodiazepine use after withdrawal of life support: association with time to death? Chest 2004; 126:286-293.
77. Clemens KE, Klaschik E. Morphine in the management of dyspnoea in ALS. A pilot study. Eur J Neurol 2008;15:445-450.
78. Walsh D, Rivera NI, Davis MP, Lagman R, Legrand SB. Strategies for pain management: Cleveland Clinic Foundation guidelines for opioid dosing for cancer pain. Support Cancer Ther 2004;1: 157-164.
79. Brody H, Campbell ML, Faber-Langendoen K, Ogle K. Withdrawing intensive life-sustaining treatment-recommendations for compassionate clinical management. N Engl J Med 1997;336:652-657.
80. Truog R, Cist AFM, Brackett SE. Recommendations for end-of-life care in the intensive care unit: the ethics committee of the Society of Critical Care Medicine. Crit Care Med 2001;29:2332-2348.
81. Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002;86:200-211.
82. Wallace SK, Ewer MS, Price KJ, Feeley TW. Outcome and cost implications of cardiopulmonary resuscitation in the medical intensive care unit of a comprehensive cancer center. Support Care Cancer 2002;10:425-429.
83. Hayashi H, Oppenheimer EA. ALS patients on TPPV. Totally locked-in state, neurologic findings and ethical implications. Neurology 2003;61:135-137.
84. Albert SM, Murphy PL, Del Bene ML, Rowland LP. A prospective study of preferences and actual treatment choices in ALS. Neurology 1999;53:278-283.
85. Borasio GD, Gelianas DF, Yanagisawa N. Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective. J Neurol 1998;245(suppl 2):S7-S12.
86. Mitsumoto H, Rabkin J. Palliative care for patients with amyotrophic lateral sclerosis "prepare for the worst and hope for the best." JAMA 2007;298:207-216.
87. Kaub-Wittemer D, Steinbuchel N, Wasner M, Laier-Groeneveld G, Borasio G. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J Pain Sympt Manag 2003;26:890-896.
88. Moss AH, Oppenheimer EA, Casey P, Cazzolli PA, Roos RP, Stocking CB, et al. Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation: advance care planning and outcomes. Chest 1996;110:249-255.
89. Curtis JR, Patrick DL. Barriers to communication about end-of-life care in AIDS patients. J Gen Intern Med 1997;12:736-741.
90. Silverstein MD, Stocking CB, Antel JP, Beckwith J, Roos RP, Siegler M. Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decision making, and life-sustaining therapy. Mayo Clin Proc 1991;66:906-913.
91. Munroe CA, Sirdofsky MD, Kuru T, Anderson ED. End-of-life decision making in 42 patients with amyotrophic lateral sclerosis. Respir Care 2007;52:996-999.
92. Astrow AB, Sood JR, Nolan MT, Terry PB, Clawson L, Kub J, et al. Decision-making in patients with advanced cancer compared with amyotrophic lateral sclerosis. J Med Ethics 2008;34:664-668.
93. Ventilation: the decision making process: the Les Turner ALS Foundation. Available from the ALS Association website: http://urlwww.alsa.org/resources/videos
94. Respiratory issues in ALS (amyotrophic lateral sclerosis) caregivers' guide. http://www.als-mda.org/publications/alscare/ch3/
95. Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs and patient, family and physician attitudes. Neurology 1993;43:438-443.
96. FiveWishes. http://www.agingwithdignity.org/catalog/
97. Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler 2001;2:159-164.
98. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives; an evidence-based review with good practice points. Eur J Neurol 2005;12:921-938.
99. Bede P, Oliver D, Stodart J. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry 2011;82:413-418.
100. Ng L, Khan F, Mathers S. Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease (review). Cochrane Database Syst Rev 2009 Oct 7;(4)CD007425.
101. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane SA, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
102. Corr B, Frost E, Markey F. Access to palliative care services by Irish ALS patients. Amyotroph Lateral Scler 2003;4:219-220.
103. Turner-Stokes L, Sykes N, Silber E, Khatri A, Sutton L, Young E. From diagnosis to death: exploring the interface between neurology, rehabilitation and palliative care in managing people with long-term neurological conditions. Clin Med 2008;8:186-191.
104. Vitacca M, Comini L, Tentorio M, Trainini D, Fiorenza D, Morini R, et al. A pilot trial of telemedicine-assisted, integrated care for patients with advanced amyotrophic lateral sclerosis and their caregivers. J Telemed Telecare 2010;16:83-88.
105. Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology 2002;59:428-431.
106. McCluskey L, Houseman G. Medicare hospice referral criteria for patients with amyotrophic lateral sclerosis: a need for improvement. J Palliat Med 2004;7:47-53.
107. Mitsumoto H, Bromberg M, Johnston W Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler 2005;6:145-154.
108. Ward AL, Sanjak M, Duffy K, Bravver E, Williams N, Nichols M, et al. Power wheelchair prescription, utilization, satisfaction, and cost for patients with amyotrophic lateral sclerosis: preliminary data for evidence-based guidelines. Arch Phys Med Rehabil 2010;91:268-272.